Urinary Nuclear Matrix Protein as a Marker for Transitional Cell Carcinoma of the Urinary Tract |
| |
| Authors: | Gennaro A. Carpinito Walter M. Stadler Joseph V. Briggman Gerald W. Chodak Paul A. Church Donald L. Lamm Paul H. Lange Edward M. Messing Robert M. Pasciak George B. Reservitz Robert N. Ross Daniel B. Rukstalis Michael F. Sarosdy Mark S. Soloway Robert P. Thiel Nicholas Vogelzang Cheryl L. Hayden |
| |
| Affiliation: | Boston City Hospital and New England Deaconess Hospital, Boston, Cambridge Urological Associates, Cambridge, Matritech, Inc., Newton and Medical/Science Analytics, Brookline, Massachusetts, University of Chicago, Weiss Memorial Hospital and Dupage Urological Associates, Chicago, Illinois, West Virginia University, Morgantown, West Virginia, University of Washington, Seattle, Washington, University of Rochester, Rochester, New York, Medical College of Pennsylvania and Hahnemann University, Philadelphia, Pennsylvania, University of Texas at San Antonio, San Antonio, Texas, University of Miami, Miami, Florida, and Dianon Systems, Stratford, Connecticut. |
| |
| Abstract: | PurposeThe purpose of this trial was to evaluate an immunoassay for urinary nuclear matrix protein, NMP22,* as an indicator for transitional cell carcinoma of the urinary tract.Materials and MethodsThree groups of subjects participated in this trial of NMP22: 1--175 with transitional cell carcinoma, 2--117 with benign urinary tract conditions and 3--375 healthy volunteers. Each subject provided a single (3 voids) urine sample for analysis at the time of study entry. Each sample was assayed for the level of NMP22.ResultsIn normal healthy volunteers and in subjects with benign conditions median NMP22 levels were 2.9 and 3.3 units per ml., respectively. Median urinary NMP22 levels in patients with transitional cell carcinoma were significantly greater than in comparison subjects. Patients with active transitional cell carcinoma had significantly greater median urinary NMP22 levels than those with no evidence of disease (6.04 versus 4.11 units per ml., p = 0.027, 1-tailed Mann-Whitney U test). We noted no effect of tumor grade, extent of disease or exposure to intravesical therapy on urinary NMP22 levels.ConclusionsNMP22 is a promising urinary tumor marker for monitoring transitional cell carcinoma. Nuclear matrix proteins are a new class of tumor markers that represent the basis for the development of assays with increased efficacy for the detection and treatment of cancer. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
